RESEARCHER PROFILE
Roberto Bianco
← Back to University of Naples Federico II
R
University of Naples Federico II
Roberto Bianco works in Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Colorectal Cancer Treatments and Studies. Recorded institutional associations include Federico II University Hospital, University of Naples Federico II.
506Publications
12,356Citations
58H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
2000 · 937 citationsInhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
2001 · 643 citationsEpidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
2001 · 548 citationsLoss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
2003 · 448 citationsAntiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
2000 · 379 citationsGemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
1999 · 362 citationsAntitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
2004 · 349 citationsAntitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
1999 · 332 citationsEnhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
2002 · 246 citationsRole of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel
2003 · 220 citationsRole of FGFR3 in bladder cancer: Treatment landscape and future challenges
2023 · 211 citationsMolecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications
2019 · 200 citationsChagas disease in Europe: A review for the internist in the globalized world
2017 · 199 citationsA phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
2005 · 179 citationsMechanisms of lapatinib resistance in HER2-driven breast cancer
2015 · 164 citationsKey cancer cell signal transduction pathways as therapeutic targets
2006 · 153 citationsIncreased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
2013 · 152 citationsVascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
2008 · 149 citationsCombination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
2003 · 148 citationsRational bases for the development of EGFR inhibitors for cancer treatment
2007 · 144 citationsInhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
2008 · 135 citationsAssociation of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer
2017 · 132 citationsAntitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
2000 · 126 citationsInteraction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy
2006 · 125 citationsThe Novel Butyrate Derivative Phenylalanine-Butyramide Protects from Doxorubicin-Induced Cardiotoxicity
2019 · 123 citations
